Clinical Research Directory

Inclusion Criteria: * Healthy men and women aged between 18 and 70 years. * Stable body weight (±5%) during the three months prior to study initiation. * Physical examination and vital signs within normal limits or clinically irrelevant for the study. * Subjects must be able to understand and willing to sign the informed consent form, and comply with all study procedures and requirements. * Ongoing pharmacological/hormonal treatment will be permitted provided it does not affect the parameters under investigation and the dosage has been stable for at least three months prior to study initiation. * Willingness to undergo all study procedures, including daily consumption of one probiotic capsule during the intervention. * Availability in terms of time and location to attend the two scheduled in-person clinical evaluation sessions. Exclusion Criteria: * Volunteers undergoing pharmacological treatment with unstable dosing (less than 3 months prior to study initiation) will be excluded, particularly if treatments: * Affect gastrointestinal function. * Include chronically prescribed stomach protectants. * Subjects with significant functional or structural abnormalities of the digestive system, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, chronic reflux, etc. * Subjects who have undergone surgical procedures resulting in permanent alterations of the digestive system (e.g., gastroduodenostomy) or bariatric surgery. * Presence of systemic intestinal, hepatic, or renal diseases, such as uncontrolled thyroid disorders, cirrhosis, inflammatory bowel disease, untreated anemia, etc. (non-alcoholic fatty liver disease will not be excluded). * Alcohol consumption exceeding the sex-specific limits (\>14 units/week for women, \>20 units/week for men). * Pregnancy, lactation, or plans to become pregnant during the study period. * Use of nutritional supplements that may affect study outcomes (e.g., weight-loss supplements, newly initiated fiber supplements, probiotics, postbiotics, etc.). * Subjects with any type of cancer currently undergoing treatment, or with less than five years since cancer remission. * Known allergy to any component of the investigational product. * Presence of cognitive and/or psychological impairments. * Anticipated poor compliance or, in the investigator's opinion, difficulty adhering to study procedures. * Participation in any weight loss or body composition modification treatments. * Use of antibiotics within 15 days prior to the baseline visit.